Corona Remedies
add_icon

Corona Remedies

1,524.10
-44.50
(-2.84%)
Market Cap
9,321.41 Cr
PE Ratio
55.87
Volume
12,565.00
Day High - Low
1,570.00 - 1,501.40
52W High-Low
1,660.80 - 1,336.60
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
9,321.41 Cr
EPS
24.43
PE Ratio
55.87
PB Ratio
14.51
Book Value
107.76
EBITDA
245.90
Dividend Yield
0.47 %
Industry
Healthcare
Return on Equity
24.65
Debt to Equity
0.23
Forecast For
Actual
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,724.40
#1 4,13,741.32
37.53
#1 54,729.00
9.71
#1 10,980
16.07
58.16
6,291.00
1,67,006.28
67.40
9,712.00
18.67
2,191
-1.02
53.89
4,241.70
1,43,558.40
62.90
11,539.40
6.99
1,911
26.24
66.58
1,341.10
1,08,330.28
23.68
28,409.50
7.12
5,291
-57.18
43.41
1,280.40
1,06,866.07
19.34
33,741.20
16.73
5,725
-15.28
60.10
2,219.40
1,01,381.93
21.81
22,909.50
13.74
3,306
#1 37.44
57.52
900.75
90,636.53
#1 18.06
23,511.00
18.55
4,615
-0.32
49.52
2,024.30
83,564.13
46.65
12,744.20
#1 20.90
2,007
7.65
38.95
1,158.80
67,303.29
19.60
32,345.60
9.43
3,484
7.59
47.48
5,392.00
64,469.45
26.53
13,458.30
3.70
2,216
1.90
37.57
Growth Rate
Revenue Growth
17.78 %
Net Income Growth
65.08 %
Cash Flow Change
21.52 %
ROE
30.84 %
ROCE
38.23 %
EBITDA Margin (Avg.)
29.51 %

Quarterly Financial Results

Quarterly Financials
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
293
316
299
295
349
364
345
Expenses
242
247
228
240
277
283
278
EBITDA
51
69
70
56
72
81
66
Operating Profit %
17 %
21 %
23 %
18 %
20 %
22 %
19 %
Depreciation
8
9
10
10
9
9
9
Interest
3
3
2
2
2
2
2
Profit Before Tax
39
57
58
44
61
70
55
Tax
9
14
13
12
15
18
14
Net Profit
30
43
45
32
46
52
41
EPS in ₹
4.90
7.03
7.35
5.16
7.55
8.55
6.75

Balance Sheet

Balance Sheet
2023
2024
2025
Total Assets
595
831
930
Fixed Assets
185
384
370
Current Assets
292
290
339
Capital Work in Progress
65
121
186
Investments
32
26
26
Other Assets
314
301
348
Total Liabilities
595
831
930
Current Liabilities
137
224
240
Non Current Liabilities
49
126
84
Total Equity
409
480
606
Reserve & Surplus
347
419
545
Share Capital
61
61
61

Cash Flow

Cash Flow
2023
2024
2025
Net Cash Flow
8
-11
0
Investing Activities
-50
-267
-84
Operating Activities
103
157
191
Financing Activities
-45
99
-107

Share Holding

% Holding
Apr 2025
Dec 2025
Promoter
72.50 %
69.00 %
FIIs
0.00 %
1.84 %
DIIs
0.00 %
6.76 %
Government
0.00 %
0.00 %
Public / Retail
0.00 %
1.36 %
Others
27.50 %
21.05 %
No of Share Holders
9
9

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.31 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
02 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
02 Jan 2026 1,347.70 1,402.95
02 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
02 Feb 2026 1,404.80 1,447.75

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 10, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 03, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 02, 2026
Announcement under Regulation 30 (LODR)-Credit RatingFeb 02, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 02, 2026
Financial Results For The Third Quarter And Nine Months Ended December 31 2025Feb 02, 2026
Board Meeting Outcome for Outcome Of Board MeetingFeb 02, 2026
Intimation Of Violation Under The Companys Code Of Conduct For Regulating Monitoring And Reporting Of Insider Trading In Securities And The SEBI (Prohibition Of Insider Trading) Regulations 2015Jan 30, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2026
Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Third Quarter And Nine Months Ended On December 31 2025Jan 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 21, 2026
Intimation Under Regulation 30-GMP Certificate Of Compliance From Eurasian Economic UnionJan 19, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 12, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 05, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJan 03, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 03, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 02, 2026
Financial Results For The Second Quarter And Half Year Ended September 30 2025Jan 02, 2026
Board Meeting Outcome for Outcome Of Board MeetingJan 02, 2026
Intimation For Updation Of CIN Of The CompanyJan 01, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 30, 2025
Closure of Trading WindowDec 29, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Second Quarter And Half Year Ended On September 30 2025Dec 26, 2025
Intimation For Appointment Of Investor Relations AgencyDec 23, 2025
Commencement Of Commercial ProductionDec 22, 2025
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements Regulations) 2015Dec 15, 2025
Intimation Pursuant To Regulation 8(2) Of The SEBI (Prohibition Of Insider Trading) Regulations 2015Dec 15, 2025
Intimation Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Dec 15, 2025
Appointment of Company Secretary and Compliance OfficerDec 15, 2025
Closure of Trading WindowDec 15, 2025
Listing of Equity Shares of Corona Remedies LtdDec 15, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Quality Fund Direct-Growth
0.57%
-52221
-0.27%
0.57%
Invesco India Consumption Fund Direct - Growth
2.19%
12281
0.57%
2.19%
Invesco India Large & Mid Cap Fund Direct-Growth
0.41%
0
0.00%
0.04%
Invesco India Smallcap Fund Direct - Growth
2.18%
0
0.00%
0.30%
Edelweiss Recently Listed IPO Fund Direct-Growth
1.75%
0
0.00%
0.24%
Franklin India Large & Mid Cap Fund Direct-Growth
0.52%
0
0.00%
0.00%
HDFC Pharma And Healthcare Fund Direct - Growth
0.56%
0
0.00%
-0.43%
Axis Equity Savings Fund Direct-Growth
0.68%
0
0.00%
0.06%
Axis Business Cycles Fund Direct-Growth
0.54%
0
0.00%
0.05%
Invesco India ELSS Tax Saver Fund Direct-Growth
0.21%
0
0.00%
0.20%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
2.13%
0
0.00%
0.20%
Invesco India Mid Cap Fund Direct-Growth
1.03%
0
0.00%
0.09%
Invesco India Multicap Fund Direct-Growth
0.84%
0
0.00%
0.09%
DSP Healthcare Fund Direct - Growth
0.58%
0
0.00%
0.06%
Kotak Consumption Fund Direct - Growth
0.53%
0
0.00%
0.08%
Kotak Healthcare Fund Direct - Growth
1.92%
0
0.00%
0.19%
Mirae Asset Healthcare Fund Direct - Growth
0.35%
0
0.00%
-0.23%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.39%
0
0.00%
-0.12%
Tata India Pharma & Healthcare Fund Direct-Growth
1.40%
0
0.00%
0.16%
WhiteOak Capital Balanced Advantage Fund Direct - Growth
0.05%
0
0.00%
0.00%
WhiteOak Capital Flexi Cap Fund Direct - Growth
0.10%
0
0.00%
0.10%
WhiteOak Capital Multi Asset Allocation Fund Direct - Growth
0.04%
0
0.00%
0.00%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
2.03%
0
0.00%
1.52%

Technical Indicators

RSI(14)
Neutral
49.90
ATR(14)
Volatile
56.01
STOCH(9,6)
Neutral
43.45
STOCH RSI(14)
Neutral
21.62
MACD(12,26)
Bearish
-4.97
ADX(14)
Strong Trend
26.00
UO(9)
Bearish
44.68
ROC(12)
Uptrend And Accelerating
3.36
WillR(14)
Neutral
-60.62